UnitedHealth Group vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Minnetonka US largest healthcare company (NYSE: UNH) at $400.3B 2024 revenue with UnitedHealthcare + Optum; 2025 leadership transition (Hemsley return, Witty departure) and suspended outlook after Change Healthcare breach and elevated medical costs.
About
UnitedHealth Group is a Minnetonka, Minnesota-based healthcare and insurance conglomerate — publicly traded on the New York Stock Exchange (NYSE: UNH) as the largest healthcare company in the United States by revenue — reporting $400.3 billion in 2024 revenues and operating through two complementary platforms: UnitedHealthcare (health insurance serving 50+ million people) and Optum (health services including OptumHealth care delivery, OptumRx pharmacy benefit management, and OptumInsight technology and analytics). Employing approximately 400,000 people globally across 500+ locations, UnitedHealth Group has been transformed by a turbulent 2024-2025 period: the Change Healthcare ransomware cyberattack (February 2024) disrupted healthcare payments for 190 million Americans; UnitedHealthcare CEO Brian Thompson was murdered in December 2024 in New York City; and CEO Andrew Witty resigned for personal reasons in May 2025, with founder-era CEO Stephen Hemsley returning to lead the company and the 2025 earnings outlook suspended amid higher-than-expected medical costs.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
UnitedHealth Group vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.